(Q36726382)

English

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

scientific article published on January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis (English)

1 reference

Europe PubMed Central

15 August 2017

multiple sclerosis

0 references

author name string

Volker Limmroth

1

1 reference

Europe PubMed Central

15 August 2017

Rolf Malessa

2

1 reference

Europe PubMed Central

15 August 2017

Uwe Klaus Zettl

3

1 reference

Europe PubMed Central

15 August 2017

Jürgen Koehler

4

1 reference

Europe PubMed Central

15 August 2017

Gudrun Japp

5

1 reference

Europe PubMed Central

15 August 2017

Peter Haller

6

1 reference

Europe PubMed Central

15 August 2017

Wolfgang Elias

7

1 reference

Europe PubMed Central

15 August 2017

Winfried Obhof

8

1 reference

Europe PubMed Central

15 August 2017

Andrea Viehöver

9

1 reference

Europe PubMed Central

15 August 2017

Uwe Meier

10

1 reference

Europe PubMed Central

15 August 2017

Arne Brosig

11

1 reference

Europe PubMed Central

15 August 2017

Joerg Hasford

12

1 reference

Europe PubMed Central

15 August 2017

Norman Putzki

13

1 reference

Europe PubMed Central

15 August 2017

Gabriele Kalski

14

1 reference

Europe PubMed Central

15 August 2017

Colin Wernsdörfer

15

1 reference

Europe PubMed Central

15 August 2017

QUASIMS Study Group

16

1 reference

Europe PubMed Central

15 August 2017

publication date

1 January 2007

1 reference

Europe PubMed Central

15 August 2017

Journal of Neurology

1 reference

Europe PubMed Central

15 August 2017

254

1 reference

Europe PubMed Central

15 August 2017

1

1 reference

Europe PubMed Central

15 August 2017

67-77

1 reference

Europe PubMed Central

15 August 2017

https://scigraph.springernature.com/pub.10.1007/s00415-006-0281-1

0 references

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0281-1

21 January 2018

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0281-1

21 January 2018

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0281-1

21 January 2018

Interferon beta in relapsing–remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose, frequently administered interferon beta

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17273808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00415-006-0281-1

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36726382&oldid=1650491694"